VFA
CBAY

Valeo Financial Advisors’s Cymabay Therapeutics CBAY Stock Holding History

Valeo Financial Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-200
Closed -$1K – 1952
2021
Q1 		$1K Buy
+200
New +$1.08K ﹤0.01% 1970

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Valeo Financial Advisors's CBAY Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Cymabay Therapeutics (CBAY) in Q2 2021, closing a stake of 200 shares — an estimated $1K sold.

Valeo Financial Advisors first reported a position in CBAY in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 113 funds tracked by Wall St. Rank hold CBAY as of Q2 2021.

  • Valeo Financial Advisors reported no remaining Cymabay Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 200 Cymabay Therapeutics shares in Q2 2021, an estimated $1K.
  • Valeo Financial Advisors first reported a position in Cymabay Therapeutics in Q1 2021 and held it in 1 quarter.
  • Valeo Financial Advisors's Cymabay Therapeutics position peaked at $1K in Q1 2021.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.